Hospital Pharmacy presents this feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest regarding a broad scope of topics are abstracted monthly.
Get full access to this article
View all access options for this article.
References
1.
AveryA.J.RodgersS.CantrillJ.A.A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis [published online ahead of print February 20, 2012]. Lancet.
2.
BlackburnD.F.YakiwchukE.M.JorgensonD.J.MansellK.D.Proposing a redefinition of pharmaceutical care. Ann Pharmacother.2012; 46(3): 447–449.
3.
CarterS.R.MolesR.WhiteL.ChenT.F.Patients' willingness to use a pharmacist-provided medication management service: the influence of outcome expectancies and communication efficacy [published online ahead of print February 29, 2012]. Res Social Adm Pharm.
4.
CharroisT.L.ZolezziM.KoshmanS.L.A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy.2012; 32(3): 222–233.
5.
GagnonL.FairchildA.PituskinE.Optimizing pain relief in a specialized outpatient palliative radiotherapy clinic: contributions of a clinical pharmacist. J Oncol Pharm Pract.2012; 18(1): 76–83.
6.
NovakC.J.HastananS.MoradiM.TerryD.F.Reducing unnecessary hospital readmissions: the pharmacist's role in care transitions. Consult Pharm.2012; 27(3): 174–179.
7.
ScottM.A.HitchW.J.WilsonC.G.LugoA.M.Billing for pharmacists' cognitive services in physicians' offices: multiple methods of reimbursement. J Am Pharm Assoc(2003).2012; 52(2): 175–180.
8.
ThomasT.KarrS.KelleyK.W.McBaneS.Overcoming barriers to scholarly activity in a clinical practice setting. Am J Health Syst Pharm.2012; 69(6): 465–467.
9.
CabralK.P.AnsellJ.Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation [published online ahead of print February 28, 2012]. Nat Rev Cardiol.
10.
HellwigT.R.PeitzG.J.GulsethM.P.High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations. Am J Health Syst Pharm.2012; 5;69(6): 490–495.
PappalardoF.ScandroglioA.M.PotapovE.Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol.2012; 78(3): 330–335.
13.
PerissinottiA.J.DotsonB.BaciewiczF.A.JrTennenbergS.D.Successful use of fondaparinux for bridging early after aortic and mitral mechanical heart valve replacement. Ann Pharmacother.2012; 46(3): e9.
14.
ScharfJ.DempfleC.E.Anticoagulation in neurointerventions: basic pharmacology and pathophysiology, current status, practical advice. Clin Neuroradiol.2012; 22(1): 3–13.
15.
WislerJ.W.BeckerR.C.Oral factor Xa inhibitors for the long-term management of ACS [published online ahead of print February 21, 2012]. Nat Rev Cardiol.
16.
ZeidanA.FaltasB.StreiffM.Dabigatran etexilate: What do hospitalists need to know?J Hosp Med.2012; 7(3): 262–269.
17.
HankeyG.J.PatelM.R.StevensS.R.; for the ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF [published online ahead of print March 6, 2012]. Lancet Neurol.
18.
IyerV.SinghH.S.ReiffelJ.A.Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use [published online ahead of print March 2, 2012]. J Cardiovasc Pharmacol Ther.
19.
LaviS.CantorW.J.CasanovaA.Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: insights from the TRANSFER-AMI trial. Am Heart J.2012; 163(2): 176–181.e2.
20.
LiuT.KorantzopoulosP.LiL.LiG.Survival benefit of new anticoagulants compared with warfarin in patients with atrial fibrillation: a meta-analysis. Int J Cardiol.2012; 156(1): 96–97.
21.
MisraU.K.KalitaJ.ChandraS.Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial [published online ahead of print March 15, 2012]. Eur J Neurol.
22.
AdcockA.K.Lee-IannottiJ.K.AguilarM.I.Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation?: a critically appraised topic. Neurologist.2012; 18(2): 102–107.
23.
AtayJ.K.FiumaraK.PiazzaG.Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clin Appl Thromb Hemost.2012; 18(2): 181–184.
24.
KansalA.R.SorensenS.V.GaniR.Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart.2012; 98(7): 573–578.
25.
Latour-PérezJ.de-Miguel-BalsaE.Cost effectiveness of anticoagulation in acute coronary syndromes. Pharmacoeconomics.2012; 30(4): 303–321.
26.
SchwenkglenksM.TowardT.J.PlentS.Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart.2012; 98(7): 544–551.
27.
ChappellJ.C.DickinsonG.MitchellM.I.Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study. Eur J Clin Pharmacol.2012; 68(3): 239–247.
28.
ErikssonN.WadeliusM.Prediction of warfarin dose: Why, when and how?Pharmacogenomics.2012; 13(4): 429–440.
29.
SchechterT.FinkelsteinY.AliM.Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost.2012; 10(3): 368–374.
30.
TruongT.ArmorB.L.Successful management of anticoagulation therapy during international travel. Pharmacotherapy.2012; 32(3): e45–49.
31.
PrandoniP.PiovellaC.SpieziaL.The optimal duration of anticoagulation in patients with venous thromboembolism: How long is long enough?Panminerva Med.2012; 54(1): 39–44.
32.
Rodriguez-CastroK.I.SenzoloM.SartoriM.T.Optimal length of anticoagulant therapy in cirrhotic patients with portal vein thrombosis [published online ahead of print March 2, 2012]. Clin Gastroenterol Hepatol.
33.
BungardT.J.SchindelT.J.GargS.BrocklebankC.Evaluation of a multi staged professional development course for practising [sic] pharmacists in anticoagulation management. Int J Pharm Pract.2012; 20(2): 107–117.
34.
CarverH.R.StudenyM.GressT.W.WoodK.A.Quality improvement in an anticoagulation clinic: development of a new treatment protocol. J Nurs Care Qual.2012; 27(2): 161–170.
35.
DawsonN.L.PorterIE2ndKlipaD.Inpatient warfarin management: pharmacist management using a detailed dosing protocol. J Thromb Thrombolysis.2012; 33(2): 178–184.
36.
HickeyK.Anticoagulation management in clinical practice: preventing stroke in patients with atrial fibrillation. Heart Lung.2012; 41(2): 146–156.
37.
AlpertJ.S.New directions in anticoagulation. Am J Med.2012; 125(3): 217–218.
38.
BecattiniC.VedovatiM.C.AgnelliG.Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res.2012; 129(3): 392–400.
39.
O'DellK.M.IgawaD.HsinJ.New oral anticoagulants for atrial fibrillation: a review of clinical trials [published online ahead of print March 12 2012]. Clin Ther.
40.
PaliwalR.PaliwalS.R.AgrawalG.P.VyasS.P.Recent advances in search of oral heparin therapeutics. Med Res Rev.2012; 32(2): 388–409.
41.
VavalleJ.P.CohenM.G.The REG-1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome [published online ahead of print March 15, 2012]. Future Cardiol.
42.
CastroT.A.HeineckI.Interventions to improve anticoagulation with warfarin. Ther Drug Monit.2012; 34(2): 209–216.
43.
CheungL.K.AgiR.HymanD.J.Warfarin resistance associated with parenteral nutrition. Am) Med Sci.2012; 343(3): 255–258.
44.
ClapauchS.H.Benchimol-BarbosaP.R.Warfarin resistance and caffeine containing beverages. Int J Cardiol.2012; 156(1): e4–5.
45.
CordierW.SteenkampV.Herbal remedies affecting coagulation: a review. Pharm Biol.2012; 50(4): 443–452.
46.
CukerA.CinesD.B.How I treat heparin-induced thrombocytopenia. Blood.2012; 119(10): 2209–2218.
47.
DenasG.PengoV.Current anticoagulant safety [published online ahead of print March 6, 2012]. Expert Opin Drug Saf.
48.
ElkayamU.GolandS.The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. J Am Coll Cardiol.2012; 20;59(12): 1116–1118.
49.
HarperP.YoungL.MerrimanE.Bleeding risk with dabigatran in the frail elderly. N Engl J Med.2012; 366(9): 864–866.
50.
LaneM.A.DevineS.T.McDonaldJRHigh-risk antimicrobial prescriptions among ambulatory patients on warfarin. J Clin Pharm Ther.2012; 37(2): 157–160.
51.
TanC.W.WardC.M.Morel-KoppM.C.Evaluating heparin-induced thrombocytopenia: the old and the new. Semin Thromb Hemost.2012; 38(2): 135–143.
52.
UchinoK.Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med.2012; 172(5): 397–402.
